Skip to main content
. 2015 Oct 30;8:245–255. doi: 10.2147/TACG.S68650

Figure 4.

Figure 4

Product-limit survival estimates of MPS VI patients who received ERT and who were treatment naïve.

Notes: Product-limit survival estimates with number of subjects at risk and 95% confidence intervals. Kaplan–Maier survival curves of ERT (n=103; blue solid line) and naïve (n=14; red dashed line) patient groups. The 95% confidence intervals are indicated by blue (ERT) or red (naïve) shaded boxes. The calculated P-values were: Log rank P=0.0006, Wilcoxon P=0.0002. Reproduced from Giugliani R, Lampe C, Guffon N, et al. Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome) – 10-year follow-up of patients who previously participated in an MPS VI Survey Study. Am J Med Genet A. 2014;164A(8):1953–1964, with permission from Johny Wiley and Sons. © 2014 Wiley Periodicals, Inc.88

Abbreviations: MPS VI, mucopolysaccharidosis VI; ERT, enzyme replacement therapy; yrs, years.